The results of studies performed on the expression of Gal 3 in epithelial cutaneous neoplasms are conflicting. Upregulation of this galectin was reported in head and neck squamous cell carcinomas (SCCs) and in oral carcinomas,33 whereas in the most common cutaneous epithelial neoplasms basal cell carcinomas (BCCs) and SCCs Gal 3 expression is clearly reduced or absent.34

In circumscribed and infiltrative BCCs, cytoplasmic Gal 3 immunoreactivity was significantly more pronounced than the nuclear immunoreactivity. Moreover, no correlation was detected between BCC tumor size and Gal 3 immunoreactivity.35 Since it is unclear whether BCCs originate from basal cells, from the outer root sheaths of the hair follicles, or from both structures, Mollenhauer et al. pointed out that Gal 3 absence in BCCs indicates an important role played by Gal 3 inactivation in the pathogenesis of BCCs.16

The findings of comparative studies on Gal 3 expression in normal human epidermis and SCCs are inconsistent. Kapucuoglou et al.35 found no differences, whereas Mollenhauer et al.16 reported a substantial reduction of Gal 3 levels in SCCs. Interestingly, Kapucuoglou et al. found a significantly higher cytoplasmic immunoreactivity in SCCs, as compared to BCCs, and suggested that this finding may indicate a different biological behavior of these two tumors.35 In SCCs, a positive correlation between the intensity of cytoplasmic Gal 3 expression and the tumor size was reported, a finding that is regarded by the authors as indication that Gal 3 may contribute to the mechanisms of tumor enlargement through its anti-apoptotic activity.

Jiang et al. reported that in both benign skin disorders with epidermal hyperplasia and epithelial skin cancers (BCCs and SCCs) there was a significant downregulation of Gal 3 immunoreactivity, which, however, was comparable among the benign disorders and the neoplasms.36 They suggested, therefore, that this finding points toward a regulatory pathway independent of the differentiation status of epidermal keratinocytes. Interestingly, since a downregulation of both, Gal 3 and DMBT-1 (protein with mucin-like structure critical for carcinogenesis) is detected in most cutaneous epithelial neoplasms, it has been hypothesized that the interactions of these factors may be implicated in the pathogenetic mechanisms of these tumors.16,36

Keratoacanthomas showed staining pattern similar to that seen in SCCs with the least differentiated outer cell layers being invariably negative.12 Jiang et al. reported that in keratoacanthomas slightly positive signals for Gal 3 were mainly localized in well-differentiated and well-arranged keratinocytes in lobular structures, whereas no signals were observed in cells with a glassy appearance in deeper areas. 36

Absent or minimal expression (predominantly cytoplasmic) of Gal 3 has been reported in the melanocytes in benign melanocytic nevi in both junctional and dermal compartments37 and in the intraepidermal component of dysplastic nevi with increasing Gal 3 expression as the lesions progress from dysplastic nevi to melanomas.38 Gal 3 expression is stronger in thin primary melanomas, as compared to benign nevi, but is progressively reduced during the development of thick and metastatic melanomas.39,40 Prieto et al. reported that in metastatic melanomas there was an increase in both, the levels of Gal 3 and the nuclear/cytoplasmic ratio of Gal 3 expression, as compared to primary melanomas and that nuclear Gal 3 expression correlated well with the prognosis of this tumor.38

In melanoma cells Gal 3 expression is mainly localized in the cytoplasm and in some cases also on the cell membranes and nucleus.39,41,42 It has been suggested that Gal 3 overexpression in primary cutaneous melanomas may reflect a more aggressive local behavior and metastasizing phenotype; thus Gal 3 may be capable of playing a significant role in the development, progression and prognosis of melanoma.42 Additionally, metalloproteinases released by melanoma cells may use Gal 3 as a substrate.39,43 Brown et al. suggested that melanoma progression is associated with a depletion of intracellular Gal 3 stores and as a consequence, the decrease in Gal 3 expression may be associated with an increased risk of metastasis and a worse overall prognosis in primary melanoma.39

Using a xenograft melanoma model with human melanoma cell lines, Vereecken et al. found that in advanced lesions Gal 3 expression was decreased and inversely correlated with aggressiveness, possibly serving as a trigger of intense proliferation.44 Serum Gal 3 concentrations are increased in patients with melanoma, probably due to increased production either by inflammatory cells or by the melanoma cells and are related to serum levels of other parameters of inflammation and Gal 3 immunoreactivity in cutaneous metastases.44,45

Li et al. reported that nuclear expression of Gal 3 was higher in primary cutaneous melanomas than in primary mucosal melanomas or in melanomas with metastases.40 Moreover, since it correlated with necrosis and the age and survival time of patients, these authors suggested that the decrease in nuclear expression of Gal 3 may represent a poor prognostic factor for melanomas.

Pozca et al. reported that elastin-derived peptides generated subsequently to elastin degradation by matrix metalloproteinases increase the invasive potential of melanoma cells and that this effect is predominantly mediated by the cell surface gal 3 receptor.46 They suggested, therefore, that a more selective and effective treatment of melanoma could be achieved by inhibition of migration and invasion of melanoma cells using antagonists of gal 3 receptor.

Adoptive T-cell transfer with ex vivo expanded tumor-reactive T-cells generated in mixed lymphocyte melanoma cell cultures is effective in the management of metastatic melanoma.47 Gal 3 and indoleamine 2,3-dioxygenase (IDO), both produced by the melanoma cells, as well as the accumulation of CD4+CD25+FoxP3 T cells suppress the expansion of melanoma-reactive T cells; on the contrary, elimination of melanoma-derived Gal 3 and IDO improve the latter.47 These observations may open the way for new and promising approaches to the treatment of metastatic melanoma using Gal 3 inhibitors.

Recently, Thode et al. using an organotypic model of cutaneous T-cell lymphoma (CTCL) showed that malignant T-cells markedly stimulate the growth of keratinocytes through secretion of galectins 1 and 3 and cause disorganization of keratinocyte stratification that resembles the early hyperproliferative phase of cutaneous lesions in CTCL.48

Mitteldorf et al. comparatively investigated the expression of Gal 3 in the skin lesions of patients with primary cutaneous anaplastic large-cell lymphomas (PCALCL), lymphomatoid papulosis (LYP), and transformed mycosis fungoides with CD30 expression (MF-T).49 They found a significantly reduced expression of this galectin in the CD30+ tumor cells of MF-T, as compared to that in CD30+ lymphoproliferative disorders (CD30 LPD), but detected no differences between PCALCL and LYP. In PCALCL Gal 3 was more often localized in the cytoplasm in contrast to LYP, in which an equal distribution in the cytoplasm and the nucleus was more common. These authors suggested that the downregulation of Gal 3 expression in MF-T (in comparison to CD30 LPD) might be used as an additional criterion to differentiate both entities, whereas the different sublocalization of the Gal 3 signal might reflect a different biological function and behavior.

EGF-mediated EGFR-ERK signaling is of outmost importance for keratinocyte migration, a decisive prerequisite for re-epithelialization of skin wounds.10 Liu et al., using cells isolated from gal 3 deficient mice, demonstrated that in the absence of Gal 3, both keratinocyte migration and skin wound re-epithelialization are impaired.50 These authors concluded that the pro-migratory effects of Gal 3 are exerted through regulation of EGFR intracellular trafficking, being carbohydrate independent.

It is known that Gal 3 serves as a receptor for advanced glycation end products (AGEs) leading to their binding and clearance. AGEs are thought to contribute to the defective skin repair in diabetic patients. Using immunohistochemistry, Pepe et al. studied the expression of Gal 3 in tissue derived from chronic wounds and apparently normal skin from the same patient, and found that Gal 3 was strongly expressed in the epidermis and the vasculature of the apparently normal skin and greatly reduced at the wound edge and in the wound bed, in which AGEs labeling was increased.51 Based on this inverse correlation between Gal 3 and AGEs, the authors suggested that Gal 3 may protect against AGEs accumulation in wound healing.51

In view of Gal 3's implications in cutaneous wound healing, McLeod et al. investigated the efficacy of human recombinant Gal 3 in the treatment of wounds in wild type and diabetic mice.52 He found that in vivo topical application of either Gal 3 or gelatin/gal 3 scaffolds did not affect wound closure, epithelial thickness, re-epithelialization, or macrophage phenotypes in the wound.

Gal 3 plays a significant role in the pathogenesis of cutaneous inflammation, since it induces macrophage, lymphoid, and myeloid cell activation,53 increases cell adhesion of myeloid cells,54 promotes chemoattraction of monocytes and macrophages,55 and regulates the response and function of diverse immune cell populations. 56

Recently, Navarro-Alvarez et al. reported that Gal 3 plasma depletion apheresis in a cutaneous inflammation porcine model through binding immuno-affinity is capable of causing a significant decrease in skin inflammation. Since this method can be also successfully used in human subjects, these authors suggested that it may represent a novel approach to the treatment of cutaneous inflammatory disorders.57

It is well known that keratinocytes of human epidermis serve as the primary target of nickel, a major contact allergen.1 Interestingly, it has been shown that epidermal exposure to nickel leads to the suppression of Gal 3 in epidermal keratinocytes.58 Moreover, intracellular Gal 3 was found to positively regulate allergic contact dermatitis in experimental animals,23 possibly through the effects of this galectin on Langerhans cells and other dendritic cells.

Saegusa et al. reported that in patients with atopic dermatitis Gal 3 expression is upregulated in inflammatory cells in the lesional skin but not in their apparently normal skin.59

These authors studied the influence of intracellular Gal 3 on the development of allergic inflammatory response in a mouse model of the acute phase of atopic dermatitis subsequent to repeated epicutaneous sensitization with ovalbumin. They detected an upregulation of Gal 3 expression at sites with inflammation induced by the sensitization. In Gal 3 deficient mice the overall inflammatory response, the thickness of the epidermis, the density of eosinophilic and monocytic infiltrate, the serum ovalbumin-specific IgE concentration, and the intensity of Th2 response were markedly decreased, as compared to Gal 3 wild-type mice.

Moreover, mice to which T-cells were engrafted from Gal 3 deficient mice sensitized with ovalbumin, showed a reduced Th2 response and skin inflammation when compared to the mice which had received T-cells from Gal 3 wild-type animals. The authors, therefore, concluded that Gal 3 is required for the development of inflammatory Th2 response to epicutaneously administered allergens, since in its absence the animals developed a Th1- polarized response. Furthermore, Saegusa et al. found out that the regulatory immune effects of Gal 3 are exerted on both dendritic cells and T-cells and suggested that Gal 3 may play an important role in the acute phase of human atopic dermatitis.10,59

These important experimental observations led Galectin Therapeutics Inc. to develop a Gal 3 inhibitor (GR-MD-02), which binds to Gal 3 and blocks its action. The therapeutic efficacy and the safety of this inhibitor were recently evaluated in a phase 1 open label clinical study in three adult patients with recalcitrant atopic dermatitis. GR-MD-02 was intravenously administered at a starting dose of 8mg/kg at baseline and then every other week for ten weeks (six infusions). This dose was then increased to 12mg/kg (every other week) for additional seven infusions. All three patients revealed improvement in their atopic dermatitis, without any significant side effects, with patient 1 achieving a 64% reduction in the Eczema Area and Severity Index (EASI) score at 24 weeks, the time of his 13th infusion. This patient has elected to remain on 24 additional weeks of therapy due to his favorable therapeutic response (Press Release, Galectin Therapeutics, Inc. 2017). Currently, an ongoing phase 2 controlled clinical investigations using various dosages of this inhibitor is expected to provide additional information on the efficacy and safety profile of GR-MD-02.

Shi et al.60 reported that about 78% of patients with systemic lupus erythematosus (SLE) and lupus-specific lesions revealed serum antibodies against Gal 3, which are capable of directly inducing lupus-like histopathologic skin changes in vivo. The cutaneous vasculitis induced by anti-Gal 3 antibody may be attributed to the function of the Gal 3 protein in mediating endothelial cell morphogenesis and angiogenesis.60

It has been recently reported that serum Gal 3 concentrations are upregulated in patients with certain autoimmune disorders and are possibly associated with their activity suggesting the implication of this galectin in the overall inflammatory autoimmune process.60-63 Shi et al. investigated the association of serum and cutaneous Gal 3 with lupus erythematosus-specific skin injuries in SLE and other autoimmune disorders.60 They found out that serum Gal 3 concentrations were significantly higher in SLE patients, as compared to healthy controls, but did not correlate either with the cutaneous disease activity or the damage score. Additionally, epidermal Gal 3 expression in the lesional skin of SLE patients was reduced, as compared to healthy controls. Based on their findings, these authors concluded that serum Gal 3 is unlikely to play a role in the pathogenesis of cutaneous lesions in SLE, but may be regarded as a potential biomarker for the assessment of SLE activity.

Serum Gal 3 total levels were found to be significantly higher in Behçet's disease (BD) patients, when compared to healthy controls. Interestingly, patients with active BD revealed significantly higher serum Gal 3 levels, as compared to inactive patients and controls and higher Gal 3-binding protein (G3BP) serum levels than the controls. Additionally, serum levels of both Gal 3 and G3BP positively correlated with the BD severity score.64,65 These results suggest that serum Gal 3 and G3BP levels may represent new biomarkers indicating the degree of BD clinical activity. It should be noted, however, that their rise in the active phase is not specific for BD, since it is also evident in patients with leukocytoclastic vasculitis.

In view of the involvement of Gal 3 in the pathogenetic mechanisms of fibrosis,66 serum concentrations of this galectin have been determined in patients with systemic sclerosis and were found to be markedly increased, as compared to healthy controls and correlating with the extent of cutaneous fibrosis.63,67 Recently, Faludi et al. reported that in patients with systemic sclerosis Gal 3 is an independent and reliable biomarker to predict all-cause and cardiovascular-related mortality, and that the serum levels of this galectin are clearly associated with advanced organ fibrosis and inflammation.68